Aliases & Classifications for Conjunctival Disease

Aliases & Descriptions for Conjunctival Disease:

Name: Conjunctival Disease 12 14
Conjunctival Diseases 52 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4251
ICD10 33 H10-H11 H11.9
ICD9CM 35 372 372.9
MeSH 42 D003229
NCIt 47 C27605
UMLS 69 C0009759

Summaries for Conjunctival Disease

MalaCards based summary : Conjunctival Disease, also known as conjunctival diseases, is related to conjunctivitis and alcoholic neuropathy, and has symptoms including eye manifestations and visual disturbance. An important gene associated with Conjunctival Disease is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Ethanol and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Conjunctival Disease

Diseases related to Conjunctival Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
id Related Disease Score Top Affiliating Genes
1 conjunctivitis 10.7
2 alcoholic neuropathy 10.3 CD40LG CD79A
3 camptodactyly vertebral fusion 10.3 CD40LG CD79A
4 diabetic peripheral angiopathy 10.3 CD40LG MRAP
5 spinal polio 10.3 CD40LG CD79A
6 rabies 10.3 CD40LG CD79A
7 unilateral retinoblastoma 10.3 CD40LG CD79A
8 mesangial proliferative glomerulonephritis 10.3 CD40LG CD79A
9 delta chain disease 10.3 CD40LG CD79A
10 discitis 10.3 CD40LG CD79A
11 spinal canal and spinal cord meningioma 10.3 CD40LG CD79A
12 trichostrongyloidiasis 10.3 CD40LG CD79A
13 cutaneous polyarteritis nodosa 10.3 CD40LG CD79A
14 mild pre-eclampsia 10.3 CD40LG CD79A
15 pediatric meningioma 10.3 CD40LG CD79A
16 tonsil cancer 10.3 CD40LG CD79A
17 indomethacin antenatal infection 10.3 CD40LG CD79A
18 postcricoid region cancer 10.3 CD40LG CD79A
19 beach ear 10.3 CD40LG CD79A
20 acute kidney tubular necrosis 10.3 CD40LG CD79A
21 diabetic angiopathy 10.2 CD40LG CD79A IL4
22 vulvar disease 10.2 CD79A RHNO1 RNASE3
23 hypoparathyroidism, x-linked 10.2 CD40LG CD79A IL4
24 atheroembolism of kidney 10.2 CD40LG CD79A
25 heart septal defect 10.2 CD40LG CD79A RNASE3
26 primary thrombocytopenia 10.2 CD40LG CD79A MRAP
27 isthmus cancer 10.2 CCL11 CD79A IL4
28 primary lacrimal atrophy 10.2 CD40LG CD79A MRAP
29 restrictive cardiomyopathy 10.2 IL5 RNASE3
30 basilar artery occlusion 10.2 CD40LG CD79A MRAP
31 penis basaloid carcinoma 10.2 CD79A RNASE3
32 partial sensory epilepsy 10.2 CD40LG CD79A
33 prostate carcinoma in situ 10.2 CD4 CD40LG
34 vulvovaginal candidiasis 10.2 CD40LG CD79A MRAP
35 filariasis 10.2 CD79A RHNO1 RNASE3
36 lymphangiectasia, intestinal 10.2 CD79A IL4 RNASE3
37 hairy tongue 10.2 CD40LG CD79A MRAP
38 pancreatic serous cystadenoma 10.2 CD40LG CD79A MRAP
39 type 2 papillary adenoma of the kidney 10.2 CD40LG CD79A IL4
40 conjunctival vascular disease 10.2 CD40LG CD79A MRAP
41 dislocation of ear ossicle 10.2 CD40LG CD79A RNASE3
42 ritscher-schinzel syndrome 1 10.2 CD40LG CD79A
43 peptidic growth factors deficiency 10.2 CCL11 IL5
44 gonadal disease 10.2 CD79A IL4 NLRP3
45 dahlberg borer newcomer syndrome 10.2 IL13 IL5
46 drug psychosis 10.2 CCL11 CD40LG CD79A
47 hallucinogen dependence 10.2 CD40LG CD79A IL4
48 celiac disease 10.2 CD40LG CD79A MRAP
49 keratomalacia 10.2 CD40LG CD79A IL4
50 ureteral lymphoma 10.2 CD40LG CD79A RNASE3

Graphical network of the top 20 diseases related to Conjunctival Disease:



Diseases related to Conjunctival Disease

Symptoms & Phenotypes for Conjunctival Disease

UMLS symptoms related to Conjunctival Disease:


eye manifestations, visual disturbance

MGI Mouse Phenotypes related to Conjunctival Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 IL5 MS4A2 NLRP3 PLG PSEN2 CCL11
2 homeostasis/metabolism MP:0005376 9.96 CD4 CD40LG CD79A IL13 IL4 IL5
3 digestive/alimentary MP:0005381 9.91 CD4 IL13 IL4 IL5 NLRP3 PLG
4 immune system MP:0005387 9.9 CCL11 CD4 CD40LG CD79A IL13 IL4
5 integument MP:0010771 9.5 PSEN2 CD4 CD40LG IL13 IL4 NLRP3
6 renal/urinary system MP:0005367 9.1 CD40LG CD79A IL4 NLRP3 PLG PSEN2

Drugs & Therapeutics for Conjunctival Disease

Drugs for Conjunctival Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 403)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
3
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
4
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
6
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
7
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
8
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
9
Glycerol Approved, Experimental Phase 4,Phase 3,Phase 2 56-81-5 753
10
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
11
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
14
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 55185 53477736 447043
15
Norgestimate Approved Phase 4,Phase 3,Phase 2 35189-28-7 6540478
16
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
17
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
18
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
19
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 124-94-7 31307
21
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
22
Latanoprost Approved, Investigational Phase 4,Phase 2 130209-82-4 5282380 5311221
23
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
24
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
25
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
27
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
28
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
29
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
30
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
31
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
32
Pheniramine Approved Phase 4 86-21-5 4761
33
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
34
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
35
Montelukast Approved Phase 4 158966-92-8 5281040
36
Ivermectin Approved, Vet_approved Phase 4,Phase 3 70288-86-7 6474909 46936176
37
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
38
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
39
Timolol Approved Phase 4 26839-75-8 33624 5478
40
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-14-8, 34580-13-7 3827
41
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
42
Tranilast Approved, Investigational Phase 4,Phase 3 53902-12-8 93543
43
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
44
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
45
Tropicamide Approved Phase 4,Phase 1 1508-75-4 5593
46
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
47
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
48
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
49
Menthol Approved Phase 4 2216-51-5 16666
50
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082

Interventional clinical trials:

(show top 50) (show all 959)
id Name Status NCT ID Phase
1 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4
4 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4
5 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4
6 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
7 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4
8 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4
9 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4
10 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
11 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4
12 Lipids of the Human Tear Film and Their Effect on Tear Stability Unknown status NCT00803452 Phase 4
13 A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery Unknown status NCT01296542 Phase 4
14 Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension Unknown status NCT02047630 Phase 4
15 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4
16 Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management Completed NCT01736449 Phase 4
17 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4
18 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4
19 Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia Completed NCT00383396 Phase 4
20 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4
21 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4
22 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4
23 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4
24 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4
25 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4
26 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4
27 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4
28 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4
29 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4
30 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4
31 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4
32 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4
33 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4
34 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4
35 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4
36 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4
37 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4
38 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4
39 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4
40 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4
41 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4
42 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4
43 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4
44 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4
45 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4
46 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4
47 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4
48 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4
49 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4
50 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4

Search NIH Clinical Center for Conjunctival Disease

Cochrane evidence based reviews: conjunctival diseases

Genetic Tests for Conjunctival Disease

Anatomical Context for Conjunctival Disease

MalaCards organs/tissues related to Conjunctival Disease:

39
Eye, T Cells

Publications for Conjunctival Disease

Articles related to Conjunctival Disease:

(show all 11)
id Title Authors Year
1
Age-related conjunctival disease in the C57BL/6.NOD-Aec1Aec2 Mouse Model of SjAPgren Syndrome develops independent of lacrimal dysfunction. ( 25758816 )
2015
2
Evaluation of total and allergen-specific secretory IgA in tears of allergic conjunctival disease patients. ( 17926109 )
2007
3
Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients. ( 17926108 )
2007
4
Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. ( 17216110 )
2005
5
Elevated levels of human alpha -defensin in tears of patients with allergic conjunctival disease complicated by corneal lesions: detection by SELDI ProteinChip system and quantification. ( 16123017 )
2005
6
Predominance of infiltrating IL-4-producing T cells in conjunctiva of patients with allergic conjunctival disease. ( 15590468 )
2004
7
Tarsal-conjunctival disease associated with Wegener's granulomatosis. ( 13129876 )
2003
8
Tear osteopontin levels in patients with allergic conjunctival diseases. ( 12486515 )
2002
9
[Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study]. ( 11987039 )
2002
10
Impression Cytology with Transfer in xerophthalmia and conjunctival diseases. ( 1490836 )
1992
11
Silver preparations in conjunctival disease. ( 16692078 )
1906

Variations for Conjunctival Disease

Expression for Conjunctival Disease

Search GEO for disease gene expression data for Conjunctival Disease.

Pathways for Conjunctival Disease

Pathways related to Conjunctival Disease according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CCL11 CD4 CD40LG CD79A IL13 IL4
2
Show member pathways
13.17 CCL11 CD4 CD40LG IL13 IL4 IL5
3
Show member pathways
12.52 CD4 CD40LG CD79A IL4 MS4A2
4
Show member pathways
12.46 CD4 IL13 IL4 IL5
5
Show member pathways
12.45 CD79A IL13 IL4 IL5 MS4A2
6
Show member pathways
12.31 CD4 CD40LG IL4 IL5
7
Show member pathways
12.3 CCL11 CD4 CD40LG IL13 IL4 IL5
8
Show member pathways
12.21 CCL11 IL13 IL4 IL5
9
Show member pathways
12.01 IL13 IL4 IL5
10 11.85 CCL11 IL13 IL4
11 11.85 CD4 CD79A IL4 IL5
12 11.77 CD4 IL4 IL5
13 11.69 IL13 IL4 IL5
14
Show member pathways
11.65 CD40LG IL4 IL5
15 11.64 CD4 IL13 IL4 IL5
16 11.61 CD40LG IL4 IL5
17 11.42 CCL11 CD40LG IL4 IL5
18 11.36 CCL11 IL13 IL4 IL5
19 11.28 CD4 CD40LG CD79A
20 11.2 CD40LG IL4 IL5
21 11.18 IL13 IL4 IL5
22 11.05 IL13 IL4 IL5
23 11 CCL11 CD40LG IL13 IL4 IL5
24 10.93 CD4 IL13 IL4 IL5
25 10.76 IL13 IL4 IL5
26 10.69 CCL11 CD4 IL13 IL4 IL5

GO Terms for Conjunctival Disease

Cellular components related to Conjunctival Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 CCL11 CD40LG IL13 IL4 IL5 NLRP3
2 extracellular space GO:0005615 9.5 CCL11 CD40LG IL13 IL4 IL5 PLG
3 external side of plasma membrane GO:0009897 9.1 CD4 CD40LG CD79A IL13 IL4 MS4A2

Biological processes related to Conjunctival Disease according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 CD4 IL4 IL5
2 B cell differentiation GO:0030183 9.61 CD40LG CD79A IL4
3 positive regulation of interleukin-4 production GO:0032753 9.54 CD40LG NLRP3
4 positive regulation of T cell proliferation GO:0042102 9.54 CD4 CD40LG IL4
5 microglial cell activation GO:0001774 9.52 IL13 IL4
6 positive regulation of mast cell degranulation GO:0043306 9.49 IL13 IL4
7 negative regulation of acute inflammatory response GO:0002674 9.48 IL4 NLRP3
8 positive regulation of interleukin-13 production GO:0032736 9.46 IL4 NLRP3
9 positive regulation of B cell proliferation GO:0030890 9.43 IL13 IL4 IL5
10 inflammatory response GO:0006954 9.43 CCL11 CD40LG IL13 IL5 MS4A2 NLRP3
11 positive regulation of immunoglobulin production GO:0002639 9.4 IL13 IL4
12 regulation of proton transport GO:0010155 9.32 IL13 IL4
13 immune response GO:0006955 9.17 CCL11 CD4 CD40LG IL13 IL4 IL5
14 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL13 IL4

Molecular functions related to Conjunctival Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL11 CD40LG IL13 IL4 IL5

Sources for Conjunctival Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....